96 results
Page 3 of 5
8-K
EX-10.1
n99y1igl
18 Jul 14
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
nd8o xl42mfrzpv
20 Mar 14
Departure of Directors or Certain Officers
12:00am
8-K
EX-99.1
9kzwzv5d78z1
20 Mar 14
Departure of Directors or Certain Officers
12:00am
8-K
7pbha6v8t5170hp
16 Sep 13
Synta Announces Fast Track Designation Granted for Ganetespib in Non-Small Cell Lung Adenocarcinoma
12:00am
8-K
EX-99.1
ek04l km7cocca6p79y7
16 Sep 13
Synta Announces Fast Track Designation Granted for Ganetespib in Non-Small Cell Lung Adenocarcinoma
12:00am
8-K
EX-99.1
1l5opjgvhdar nrj9zb
29 Jul 13
Synta Announces ENCHANT-1 Breast Cancer Results Support Transition to Second Stage of Trial
12:00am
8-K
EX-10.1
zskz75mumkkw g4w
13 Dec 12
Synta Pharmaceuticals Announces $60 Million Registered Direct Common Stock Offering
12:00am
8-K
EX-1.1
noct87ms
6 Jan 12
Synta Pharmaceuticals Prices Public Offering of Common Stock
12:00am
424B5
j0rlxaii 9oq
15 Apr 11
Prospectus supplement for primary offering
12:00am